H. Roché

830 total citations
35 papers, 596 citations indexed

About

H. Roché is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, H. Roché has authored 35 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in H. Roché's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (4 papers). H. Roché is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (4 papers). H. Roché collaborates with scholars based in France, United States and Belgium. H. Roché's co-authors include Éric Bouffet, Pierre Canal, Thierry Philip, A Robert, J Bernard, Christine Chevreau, Jean‐Marc Bachaud, Justin Teissié, P. Giraud and Marie‐Pierre Rols and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of the New York Academy of Sciences.

In The Last Decade

H. Roché

34 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Roché France 12 250 177 168 115 102 35 596
Angela Queisser Germany 15 180 0.7× 240 1.4× 106 0.6× 114 1.0× 96 0.9× 18 603
Eikichi Okada Japan 11 114 0.5× 277 1.6× 128 0.8× 133 1.2× 43 0.4× 32 547
Hiromi Kanno Japan 13 112 0.4× 254 1.4× 74 0.4× 136 1.2× 175 1.7× 31 619
Masaru Tsumuraya Japan 18 269 1.1× 358 2.0× 63 0.4× 158 1.4× 85 0.8× 32 827
Joseph D. DiDomenico United States 13 166 0.7× 168 0.9× 75 0.4× 66 0.6× 59 0.6× 34 566
Massimiliano Mazza Italy 18 309 1.2× 238 1.3× 52 0.3× 147 1.3× 178 1.7× 42 725
Xiao–Tang Kong United States 12 190 0.8× 339 1.9× 34 0.2× 87 0.8× 80 0.8× 51 679
Jan Sperveslage Germany 14 172 0.7× 183 1.0× 68 0.4× 118 1.0× 65 0.6× 26 549
H. I. Robins United States 11 126 0.5× 235 1.3× 70 0.4× 137 1.2× 125 1.2× 20 575
Hideaki Ueno Japan 11 148 0.6× 123 0.7× 65 0.4× 56 0.5× 56 0.5× 38 441

Countries citing papers authored by H. Roché

Since Specialization
Citations

This map shows the geographic impact of H. Roché's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Roché with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Roché more than expected).

Fields of papers citing papers by H. Roché

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Roché. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Roché. The network helps show where H. Roché may publish in the future.

Co-authorship network of co-authors of H. Roché

This figure shows the co-authorship network connecting the top 25 collaborators of H. Roché. A scholar is included among the top collaborators of H. Roché based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Roché. H. Roché is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gonçalvès, Anthony, Jean‐Yves Pierga, Jean-­Marc Ferrero, et al.. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology. 26(8). 1692–1697. 14 indexed citations
2.
Martín, Miguel, SA Hurvitz, John F. Kennedy, et al.. (2009). 5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC). European Journal of Cancer Supplements. 7(2). 260–260. 1 indexed citations
3.
Kerbrat, Pierre, H. Roché, P. Fumoleau, et al.. (2005). Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results. Journal of Clinical Oncology. 23(16_suppl). 660–660. 5 indexed citations
4.
Baselga, José, P. Fumoleau, Rámón Colomer, et al.. (2004). Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Journal of Clinical Oncology. 22(14_suppl). 544–544. 14 indexed citations
5.
Monnier, Alain, M Namer, H. Roché, et al.. (2004). Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials. Journal of Clinical Oncology. 22(14_suppl). 551–551. 1 indexed citations
6.
Rols, Marie‐Pierre, Jean‐Marc Bachaud, P. Giraud, et al.. (2000). Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Research. 10(5). 468–474. 84 indexed citations
7.
Baranzelli, M.C., Éric Bouffet, M Portas, et al.. (1998). An attempt to treat pediatric intracranial αFP and βHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. Journal of Neuro-Oncology. 37(3). 229–239. 46 indexed citations
8.
9.
Roché, H., Pierre Kerbrat, Paul Rebattu, et al.. (1993). Phase II Trials of Tetrahydropyranyl-Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma. American Journal of Clinical Oncology. 16(2). 137–139. 4 indexed citations
10.
Roché, H., S. Jozan, Claude P. Muller, et al.. (1993). Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2). International Journal of Cancer. 54(4). 663–668. 8 indexed citations
11.
Chatelut, Étienne, et al.. (1993). Severe Fluorouracil Toxicity in a Patient With Dihydropyrimidine Dehydrogenase Deficiency. JNCI Journal of the National Cancer Institute. 85(19). 1602–1603. 52 indexed citations
12.
Philip, Thierry, J M Zucker, J Bernard, et al.. (1991). Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?. Journal of Clinical Oncology. 9(6). 1037–1044. 119 indexed citations
13.
Chatelut, Étienne, M Forni, Pierre Canal, et al.. (1991). Teniposide and cisplatin given by intraperitoneal administration: Preclinical and phase I/pharmacokinetic studies. Annals of Oncology. 2(3). 217–221. 5 indexed citations
14.
Canal, Pierre, M Forni, Christine Chevreau, et al.. (1991). Chronopharmacokinetics of doxorubicin in patients with breast cancer. European Journal of Clinical Pharmacology. 40(3). 287–291. 25 indexed citations
15.
Roché, H., et al.. (1989). Curability of third ventricular region tumours. Acta Neurochirurgica. 98(1-2). 19–24. 5 indexed citations
16.
Roché, H., et al.. (1989). Stage IE Nonhodgkin’s Lymphoma of the Testis: A Need for a Brief Aggressive Chemotherapy. The Journal of Urology. 141(3 Part 1). 554–556. 16 indexed citations
17.
Canal, Pierre, et al.. (1987). PHARMACOKINETICS OF HIGH‐DOSE IV ALIZAPRIDE IN PREVENTION OF CISPLATIN‐INDUCED EMESIS. Fundamental and Clinical Pharmacology. 1(3). 213–217. 2 indexed citations
18.
Bernard, J, Thierry Philip, J. M. Zucker, et al.. (1987). Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?. Journal of Clinical Oncology. 5(12). 1952–1959. 41 indexed citations
19.
Canal, Pierre, et al.. (1986). Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing krebs II ascitic tumors. European Journal of Cancer and Clinical Oncology. 22(7). 765–771. 4 indexed citations
20.
Canal, Pierre, R. Bugat, Caroline Michel, et al.. (1985). Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma. Cancer Chemotherapy and Pharmacology. 15(2). 149–52. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Queisser Breakdown of academic impact, for papers by Eikichi Okada Breakdown of academic impact, for papers by Hiromi Kanno Breakdown of academic impact, for papers by Masaru Tsumuraya Breakdown of academic impact, for papers by Joseph D. DiDomenico Breakdown of academic impact, for papers by Massimiliano Mazza Breakdown of academic impact, for papers by Xiao–Tang Kong Breakdown of academic impact, for papers by Jan Sperveslage Breakdown of academic impact, for papers by H. I. Robins Breakdown of academic impact, for papers by Hideaki Ueno
Rankless by CCL
2026